Title: Development and evaluation of a predictive model of upper gastrointestinal bleeding in
liver cirrhosis
Version: 2 Date: 24 Dec 2024
Reviewer's report:
The authors have provided a thorough explanation and revisions. It is now clear that this is a
retrospective case-control study, and all patients had no history of UGIB at baseline. This is a
critical point, as patients with a history of UGIB are at higher risk for rebleeding.
I suggest minor revision:
First, change "no previous history of gastrointestinal bleeding" to the exclusion criteria (i.e.,
"patients with a history of gastrointestinal bleeding were excluded").
Second, expand the limitations section to address the absence of data on patients’ use of non-
selective beta-blockers (NSBBs) and antiviral therapies, as these factors could influence the
outcomes.
Finally, avoid using the term “matched,” as it may raise concerns about the randomization
process and the lack of a clear 1:1 or 1:2 matching ratio. Instead, revise this description to:
"These patients were compared with 151 patients with cirrhosis hospitalized during the same
period at the same hospital, who were discharged within six months without developing UGIB."
This revised phrasing indicates that all non-UGIB patients during this period were included.
Title: Development and evaluation of a predictive model of upper gastrointestinal bleeding in
liver cirrhosis
Version: 2 Date: 24 Dec 2024
Reviewer's report:
The authors have provided a thorough explanation and revisions. It is now clear that this is a
retrospective case-control study, and all patients had no history of UGIB at baseline. This is a
critical point, as patients with a history of UGIB are at higher risk for rebleeding.
I suggest minor revision:
First, change "no previous history of gastrointestinal bleeding" to the exclusion criteria (i.e.,
"patients with a history of gastrointestinal bleeding were excluded").
Second, expand the limitations section to address the absence of data on patients’ use of non-
selective beta-blockers (NSBBs) and antiviral therapies, as these factors could influence the
outcomes.
Finally, avoid using the term “matched,” as it may raise concerns about the randomization
process and the lack of a clear 1:1 or 1:2 matching ratio. Instead, revise this description to:
"These patients were compared with 151 patients with cirrhosis hospitalized during the same
period at the same hospital, who were discharged within six months without developing UGIB."
This revised phrasing indicates that all non-UGIB patients during this period were included.
Please review this paper.
user
Title: Development and evaluation of a predictive model of upper gastrointestinal bleeding in
liver cirrhosis
Version: 2 Date: 24 Dec 2024
Reviewer's report:
The authors have provided a thorough explanation and revisions. It is now clear that this is a
retrospective case-control study, and all patients had no history of UGIB at baseline. This is a
critical point, as patients with a history of UGIB are at higher risk for rebleeding.
I suggest minor revision:
First, change "no previous history of gastrointestinal bleeding" to the exclusion criteria (i.e.,
"patients with a history of gastrointestinal bleeding were excluded").
Second, expand the limitations section to address the absence of data on patients’ use of non-
selective beta-blockers (NSBBs) and antiviral therapies, as these factors could influence the
outcomes.
Finally, avoid using the term “matched,” as it may raise concerns about the randomization
process and the lack of a clear 1:1 or 1:2 matching ratio. Instead, revise this description to:
"These patients were compared with 151 patients with cirrhosis hospitalized during the same
period at the same hospital, who were discharged within six months without developing UGIB."
This revised phrasing indicates that all non-UGIB patients during this period were included.
assistant